Supplementary Figure 5. In vivo long-term human hematopoietic reconstitution from coRAG2-targeted healthy donor-derived HSPCs. (A) FACS-based quantification of bone marrow (BM) and (B) spleen (SP) primary human engraftment (hCD45+ HLA A-B-C+) derived from coRAG2-targeted fresh CB HSPCs. Each FACS plot represents an individual mouse. (C) Endpoint analysis (22 weeks post-Tx) of human hematopoietic lineage distribution in the BM and peripheral blood of immunocompetent mice (NSG). CD235+ (erythroid), CD3+ (T-cells), CD19+ (B-cells), CD14+ (monocytes); n=5 mice (mock), n=11 (coRAG2-GT). (D) CD3+ T cell subsets (CD4+, CD8+, CD4+CD8+) derived in the spleen of NSG mice from (B) engrafted with coRAG2-GT HSPCs.